CymaBay Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.cymabay.com
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02252835
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT02063997
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
- Conditions
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01416402
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01399008
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
- Conditions
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01336686
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01035879
- Locations
- 🇺🇸
Impact Clinical Trials, Los Angeles, California, United States
🇺🇸dgd Research, Inc., a Cetero Research Co., San Antonio, Texas, United States
🇺🇸United Medical Associates, Binghamton, New York, United States
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
- Conditions
- Interventions
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT00814372
- Locations
- 🇮🇳
Mediciti Hospital, Hyderabad, India
🇮🇳Diabetes Thyroid Hormone Research Institute Pvt. Ltd., Indore, India
🇮🇳Fortis Hospital, Jaipur, India
Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT00701883
- Locations
- 🇺🇸
Dallas Diabetes and Endocrine Center, Dallas, Texas, United States
🇺🇸Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States
🇺🇸Genesis Research International, Indianapolis, Indiana, United States
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00422487
- Locations
- 🇺🇸
Diabetes and Glandular Disease Research Associates, San Antonio, Texas, United States
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT00353587
- Locations
- 🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States
🇺🇸Associated Pharmaceutical Research Center, Inc., Buena Park, California, United States
🇺🇸Radiant Research - Greer, Greer, South Carolina, United States